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Background. There is an insuﬃcient remyelination in the lesions of multiple sclerosis (MS). One of the factor that was found to
promote remyelination is neuregulin-1 which is the ligand of ErbB4. Immune cells have been implicated in neurogenesis and
oligodendrogenesis. Aims. We studied the expression of ErbB4 in the immune cells of patients with relapsing remitting (RR)
multiple sclerosis (MS) and healthy controls. Methods. ErB4 expression in immune cells was studied by ﬂow cytometry without
stimulation or with stimulation with anti-CD3 and anti-CD28 monoclonal antibodies or in the presence of interferon-g or TNF-α
as well as by immunoprecipitation and Western blot, and its mRNA was studied by real-time PCR. Results. We found reduced
levels of ErbB4 in the total PBMCs and in T cells, monocytes, and B cells of RR MS patients. Similarly, the ErbB4 RNA levels were
reduced in the immune cells of patients with RR-MS. Stimulation via CD3 and CD28 signiﬁcantly upregulated the expression of
ErbB4 on immune cells healthy individuals. This eﬀect was weaker in the patients group. Conclusion. ErbB4 may play a role in
the proliferation of oligodendrocyte progenitor cells, diﬀerentiation of oligodendrocytes, and remyelination, and, therefore, the
reduced ErbB4 expression in immune cells of patients with RR-MS may contribute to insuﬃcient remyelination that occurs in the
disease.
1.Introduction
Multiple sclerosis (MS) is a chronic inﬂammatory demyeli-
nating disease of the central nervous system that is respon-
sible for the most common cause of neurological disability
in young adults [1]. MS plaques are characterized by the
presence of immune cells inﬁltration, demyelination, death
of mature oligodendrocytes axonal damage, and neurode-
generation [2]. Neuronal precursor cells (NPCs) and oligo-
dendrocyte precursor cells (OPCs) are present MS lesions
[3], and the process of remyelination exists in the lesions of
MS [4, 5]; however, this process is mostly insuﬃcient and
fail to remyelinate successfully. Neuregulins are a family of
ligands that exert trophic eﬀects on both neurons and glia
via their receptors ErbB2, ErbB3, and ErbB4. It was shown
that a soluble isoform of neuregulin-1, glial growth factor
2(GGF2), promotes survival and proliferation of glial cells
and their progenitors and enhances remyelination in vivo
[6–8].ErbB4hasbeenshowntoparticipateinwidespectrum
of functions and to take a crucial role in the development of
the nervous system and the heart as well as in diseases like
cancer and schizophrenia [9–12]. Moreover, an upregulated
expression of ErbB4 was seen on surviving oligodendrocytes
and on reactive microglial cells in and around MS lesions,
where myelin and oligodendrocyte depletion occur and was
found to be expressed on lymphocytes in lymph nodes [13].
It was recently reported that neuregulin-1 is involved in
immune regulation [14].
It has long been suggested that the immune system may
have a role in assisting the repair and regeneration of the
central nervous system (CNS) damaged tissue by myelin-
reactive T cells and T cell-derived cytokines [15, 16]b y
speciﬁcally activated blood-borne myeloid cells [17–19].
In view of the potential role of ErbB4 expression in
myelin regeneration in MS and neuroregenerative potential
of the immune activity, the aim of the present study was to2 Multiple Sclerosis International
Table 1: Study Participants.
Participants Blood donors (n)A g e ( y r s )F e m a l e : m a l e
All RR MS patients 18 34.7 ± 14.2 12:6
Untreated patients 7 32.1 ± 8.5 5:2
Interferon-β-treated patients 11 36.2 ± 9.9 7:4
Healthy controls 15 35.6 ± 6.8 10:5
investigatetheexpressionproﬁleofErbB4inimmunecellsof
patients with MS.
2. Methods
Patients with MS attending the Neuroimmunology Clinic
at the Tel Aviv Sourasky Medical Center were included in
the study. After the participants had given their informed
consent, blood samples were drawn from 13 patients with
deﬁnite relapsing remitting MS (RR-MS) according to
revisedMcDonaldetal.criteriaand10aged-matchedhealthy
controls (HC) (Table 1). Peripheral blood mononuclear
cells (PBMCs) were isolated from venous blood samples
by centrifugation over Ficoll-Paque (Amersham biosciences
Uppsala, Sweden). ErbB4 receptor expression in PBMCs
was studied by ﬂow cytometry using phycoerythrin (PE)
conjugated mouse monoclonal antibodies (mAb) against
CD3, CD14, and CD19 (R&D Systems) as well as intra-
cellular staining for ErbB4 with mouse andhuman ErbB4
mAb (Santa Cruz) and allophycocyanin-(APC-)conjugated
F(ab)2 against human Fc (Jackson ImmunoReasearch) and
the appropriate isotype controls. In a further experiment,
PBMCs of 5MS patients and 5HC were cultured for 24hrs
with either anti-CD3 mAb and anti CD28 mAb (R&D
Systems) or with the corresponding isotype controls for
24hrs or in the presence of interferon-γ 100ng/mL or
TNF-α 100ng/mL for 24hrs. The detection of these mol-
ecules was done by FACScan ﬂow cytometer (Beckton
Dickinson). The analysis was done by CellQuest Software
(Beckton Dickinson) for the measurement of the speciﬁc
mean ﬂuorescence intensity (MFI) of ErbB4 on the detected
cells and the percentages of ErbB4 positive cells.
In addition ErbB4 expression in PBMCs was studied by
immunoprecipitation and Western blot analyses. Large cell
carcinoma H661 cell line with high expression of ErbB4
was used as positive control, while H1299 human lung
adenocarcinoma cell line was used as negative control.
PBMCs were extracted using buﬀer RIPA. Insoluble material
was removed by 15 min centrifugation (12,000× g) at 4◦C.
Supernatants (0.5mg protein) were incubated for 2h at 4◦C
with monoclonal ErbB4 antibody, followed by additional
incubation for 1h at 4◦C with protein G Agarose beads.
Immunocomplexes were washed twice with buﬀer PBS-
Tween and once with PBS. The beads were suspended
in Laemmli’s Sample buﬀer, boiled for 5min, resolved by
means of 10% SDS-PAGE, and were immunoblotted with
anti-ErB-4 polyclonal antibody. During the immunoprecip-
itation, immediately after extraction, we determined the
protein level of all samples using Bradford reagent, after we
incubate similar amounts of total proteins with the anti-
ErbB4 antibody and further incubate with bead, we loaded
the same amount of supernatant. Therefore, we assume
that the same amounts of supernatant were loaded on
the gel.
Total RNA was prepared from PBMCs using an Easy
RNA puriﬁcation kit (Biological Industries) according to the
manufacturer’s instructions. The total RNA samples were
routinely treated with Turbo-DNase (Ambion) to prevent
possible genomic DNA contamination. Before the real-time
qRT-PCR reactions studied, the absence of residual genomic
DNA contamination were tested using PCR reaction with
GAPDH primers of samples that did not undergo in vitro
transcriptionreaction.ThetotalRNAof1μgwastranscribed
with random hexamers using Reverse iT transcriptase (Verso
cDNA kit) following the manufacturer’s instructions. Real-
time qRT-PCR was performed on a ABI Prism 7900HT
Instrument (Applied Bioscience). ErbB4 mRNA expression
was tested by qRT-PCR performed as follows: 94◦Cf o r1 0
minutesand45cyclesasfollowing:94◦Cfor15seconds,60◦C
for 15 seconds, and 72◦C for 15 seconds. The melting curve
analysis was routinely used for each reaction. The GAPDH
gene was run in parallel for internal control for each reaction
set. The GAPDH gene was run in parallel for internal control
for each reaction set. The uniformity of GAPDH expression
in PBMCs was tested by GeneVestigator program, analyzing
severaldiﬀerentmicroarraysstudies.GAPDHexpressionwas
independent of any PBMC treatment in healthy individuals
and in both groups of RR-MS patients as was described
before [20].The oligonucleotide primer sequences used were
ErbB4 forward primer: 5 -GGC TGC TGA GTT TTC AAG
GATG-3  and ErbB4 reverser primer 5 -GCT TCATAC GAT
CAT CAC CCT GA-3 , GAPDH forward primer 5 -ACC-
ACAGTCCATGCCATCAC-3  and GAPDH reverse primer 5 
TCCACCACCTGTTGCTGTA-3.
The data presented for RNA expression is a calculated
relative quantiﬁcation values according ABI PRISM 7900HT
software and normalized against GAPDH ± S.E.
All the data are presented as mean ± S.E. Statistical
analyses for comparing the ErbB4 expression levels between
the study groups were carried out by Student’s t-test.
3. Results
We ﬁrst compared the ErbB4 expression in PBMCs of
patients with RR-MS and age-matched HC by ﬂow cytom-
etry and found that the mean ﬂuorescence intensity (MFI) of
ErbB4 in PBMCs of patients with RR-MS was signiﬁcantly
lower (37.8 ± 2.8) than in HC (60.0 ± 5.1, P = 0.002)Multiple Sclerosis International 3
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Figure 1: ErbB4 expression in unstimulated PBMCs of patients with RR-MS and aged matched healthy controls as was measured by ﬂow
cytometry.Themeanﬂuorescenceintensity(MFI)ofErbB4inPBMCsofpatientswithRR-MSwassigniﬁcantlylowerthanthatinPBMCsof
healthy controls (a). The MFI of ErbB4 on unstimulated T cells, monocytes, and B cells of patients with RR-MS was signiﬁcantly reduced as
compared with healthy controls (b).After immunoprecipitation with monoclonal ErbB4 antibody, the cell lysates were processed by Western
blot analysis and probed by polyclonal antibody. Large cell carcinoma H661 cell line was used as positive control (PC). H1299 human lung
adenocarcinoma cell line was used as negative control (NC). The donors here are diﬀerent from those that are described in ﬁgure a and b:
H1-2 are healthy controls, and P1-5 are for RR-MS patients (c).
(Figure 1(a)).However,nosigniﬁcantdiﬀerenceswerefound
in the comparison of the percentages of ErbB4-positive
PBMCs (39.7 ± 1.3% in the RR-MS versus 41.3 ± 1.4 in the
HC, P = 0.61).
We thereafter examined the expression of ErbB4 in the
diﬀerent cell types among PBMCs (T cells = CD3+ cells,
monocytes = CD14+ cells and B cells = CD19+ cells) in the
study groups (Figure 1(b)). We found that the MFI of ErbB4
expression in T cells was lower in RR-MS patients (22.2 ±
3.3) than in HC (37.5 ± 2.4, P = 0.002), the MFI of ErbB4
expression in monocytes was lower in RR-MS patients (88.5
± 11.5) as compared to HC (135.7 ± 8.9, P = 0.006), and4 Multiple Sclerosis International
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Figure 2: The levels of ErbB4 mRNA expression in PBMCs were
studied by real-time relative RT-PCR in 10 RR-MS and 10 age-
and sex-matched healthy controls. Normalization of ErbB4 mRNA
expression was done with regards to the GAPDH mRNA levels of
expression.
the ErbB4 expression in B cells was lower in RR-MS patients
(39.8 ± 4.9) as compared to HC (56.2 ± 3.9, P = 0.018).
Again similar percentages of ErbB4, positive cells subtypes
were found between the patient group and the HC group.
An average of 54.2 ± 2.0% of the T cells in the patients
versus 57.0 ± 2.1% in HC, 16.5 ± 1.5% of the monocytes
in the patients versus 15.0 ± 1.5% in HC and 7.7 ± 0.9 of
the B cells in the patients versus 8.3 ± 0.9 in HC. All these
comparisons of percentage of positive cells were statistically
insigniﬁcant.
In order to conﬁrm our observations, we also studied
the expression of the ErbB4 protein by immunoprecipitation
and western blotting. Similarly, ErbB4 was detected at the
expected molecular weight range (180kDa) in PBMCs of
2HC but not in PBMCs of 5RR-MS patients (Figure 1(c)).
In order to further explore the diﬀerences of ErbB4
expression between our study groups, we studied the mRNA
level of expression of ErbB4 by real-time PCR and found
signiﬁcant lower relatives expression of ErbB4 mRNA in RR-
MS patients (1067.0 ± 239.0) as compared to HC (1903.1 ±
265.3, P = 0.030) (Figure 2).
We further studied the stimulatory eﬀect of anti-
CD3/CD28 mAb on the expression of ErbB4 on the PBMCs
in a diﬀerent set of participants (Figure 3). Stimulation with
anti CD3/CD28 mAb upregulated the expression of ErbB4
to a signiﬁcantly lesser extent in the MS patients group,
the average of the ratios of ErbB4 MFI between with anti-
CD3/CD28 mAb and isotype controls (average ratio ± S.D =
3.5 ± 1.6) as compared to HC (6.2 ± 1.6, P = 0.005). In both
patients group and HC group, there was an upregulation of
the ErbB4 after stimulation with anti-CD3/CD28 mAb, but
this eﬀect in the patients group (60.8 ± 18.4) did not reach
the levels of MFI in the HC (106.4 ± 18.8, P = 0.04). No
diﬀerences were found in the percentages of PBMCs positive
ErbB4 between MS patients and HC after stimulation with
anti-CD3/CD28 mAb (average percentages for MS patients
± S.D = 13.2 ± 9.7, P = 0.038 and in HC = 13.0 ±
6.0, P<0.001). No signiﬁcant eﬀect was found on the
ErbB4MFIafter24hrsincubationwithinterferon-γ between
the patients group (the MFI average ratio versus without
cytokine = 1.5 ± 1.1) and HC (1.2. ± 0.6, P = 0.591) or on
the percentages of ErbB4-positive PBMCs (the percentages
average ratio versus without cytokine ± S.D = 20.7 ± 39.8
P = 0.370) and in HC (9.9 ± 16.5, P = 0.386). Similarly,
no signiﬁcant eﬀect was found on the ErbB4 MFI after
24hrs incubation with TNF-α between the patients group
(the MFI average ratio versus without cytokine = 1.1 ± 0.6)
and HC (0.7 ± 0.3, P = 0.240) or on the percentages of
ErbB4-positive PBMCs (the percentages average ratio versus
without cytokine of ErbB4 + PBMCs in the patients group
(10.9 ± 20.8, P = 430) and in the HC (1.69 ± 1.8, P = 438).
We did not ﬁnd diﬀerences between untreated patients and
patients that were treated with interferon-b with regards to
the expression of ErbB4.
4. Discussion
Neuregulins have been shown in to support several types
of glial cells by enhancing their proliferation, survival, and
diﬀerentiation as well as the enhancement of remyelination
intheadultbrain[6].Itisimportant tonote,thattheprocess
of remyelination is mostly inconsistent in MS lesions, and
many lesions fail to remyelinate successfully. Furthermore,
in part of the patients the MS lesion is mostly characterized
by oligodendrocyte apoptosis [2]. This failure contributes to
irreversible axon loss and progressive neurological deteriora-
tion [21, 22].
In the present study, we looked for the expression of the
natural receptor of neuregulins, ErbB4, and found for the
ﬁrst time that ErbB4 levels are reduced in the PBMCs of
patients with RR-MS. This reduced expression was found
in all cell subset we studies: T cells, monocytes, and B
cells and was also demonstrated in the transcripts levels of
ErbB4 mRNA. The stimulation via CD3/CD28 upregulated
the expression of ErbB4 in HC and had a weaker eﬀect
in the patients with MS. We assume that ErbB4 may play
a role in the proliferation of oligodendrocyte progenitor
cells and in the diﬀerentiation of oligodendrocytes, and
therefore, an inadequate ErbB4 expression may be related
to insuﬃcient remyelination that occurs in the disease. Our
results disclose a new unreported aspect that is related to
the deviated immunity in MS that includes the increased
production of proinﬂammatory cytokines, such as IFN-γ
from T cells and IL-12, IL-18 and IL-23 from monocytes
and dendritic cells [23–27], the loss of function of Treg
cells, such as CD4+CD25+ T cells and CD46-mediated Tr-
1 cells [28, 29], as well as of suppressor CD8+ T cells [30,
31] and the reduction in immune-mediated neurotrophins,
a n dn o g g i np r o d u c t i o n[ 20, 32, 33]. In MS, there is
an increased proinﬂammatory activity and a presumed
decreased immune-mediated regulatory, neuroprotective,
and neuroregenerative activity. We suggest that the reduced
expression and responsiveness to CD3/CD28 stimulation of
ErbB4 expression on immune cells in patients with MSMultiple Sclerosis International 5
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Figure 3: ErbB4 expression in PBMCs of 5 patients with RR-MS and 5 age- and sex-matched healthy controls (HC) was studied after 24 hrs
incubation with anti-CD3/CD28 mAb (white histograms) or their isotype controls (grey histograms). The stimulatory eﬀect via CD3/CD28
on the MFI of ErbB4 was signiﬁcantly higher in the HC as compared to the patients.6 Multiple Sclerosis International
may be related to an insuﬃcient immune mediation of
remyelination and oligodendrogenesis in MS.
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